Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Israel's BioLineRx has signed a worldwide exclusive license agreement with the Hebrew University of Jerusalem and Tel Aviv University for the development and commercialization of a treatment for inflammatory disease.
Subscribe to our email newsletter
BL-4020 is a peptide designed to function as an anti-inflammatory agent in various diseases such as allergic asthma and colitis. In preclinical trials conducted at the Hebrew University of Jerusalem, BL-4020 has been shown to be effective in a wide variety of animal models of inflammation including asthma, colitis among others.
“Inflammation is the cause of many significant diseases and we believe that BL-4020 offers the potential for a highly effective and safe therapy utilizing a novel mechanism of action,” said Morris Laster, CEO of BioLineRx. “BL-4020 is a promising addition to our rich pipeline of exciting and innovative drug candidates, and we are pleased to continue our fruitful collaborations with both the Hebrew and Tel Aviv Universities.”
Currently, inflammatory diseases are treated mainly with non-steroidal anti-inflammatory drugs, or with steroids, both of which can have severe side-effects.